A double-blind, placebo-controlled, randomized trial of XP-828L (800 mg) on the quality of life and clinical symptoms of patients with mild-to-moderate psoriasis.

Abstract

In a placebo-controlled clinical trial, the dietary supplement XP-828L (commercialized as Dermylex) demonstrated potential to reduce symptoms associated with mild-to-moderate psoriasis at a dose regimen of 5 g daily for 56 days. However, recent in vivo data in humans and animals suggest a daily dose of 800 mg could be more efficient than a 5-g dose. However, no well-structured clinical study has confirmed this hypothesis. The goal of the present study is to examine the effect of XP-828L at a daily dose of 800 mg on the quality of life and disease severity in patients with mild-to-moderate psoriasis. XP-828L at 800 mg per day (n=16) or placebo (n=10) was given orally for 56 days. Efficacy was measured by the Dermatology Life Quality Index (DLQI), Psoriasis Area and Severity Index (PASI), and itching sensation scores at day 1 and day 56. The DLQI and PASI scores and itching sensation decreased significantly by day 56 in subjects taking XP-828L compared to placebo (p less than 0.05). In summary, daily administration of 800 mg XP-828L for 56 days is adequate to improve the quality of life and decrease disease severity in patients with mild-to-moderate psoriasis.

• Authors: Rejean Drouin, Olivier Moroni, Kim Cantin, Christina Juneau
• Journal: Alternative medicine review : a journal of clinical therapeutic (Altern Med Rev) Vol. 13 Issue 2 Pg. 145-52 (Jun 2008) ISSN: 1089-5159 [Print] United States
• PMID: 18590350 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Milk Proteins
• XP-828l

Topics

• Administration, Oral
• Adult
• Dietary Supplements
• Double-Blind Method
• Female
• Humans
• Male
• Milk Proteins (administration & dosage)
• Psoriasis (drug therapy, psychology)
• Quality of Life